Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
about
Challenges in the clinical utility of the serum test for HER2 ECDDurable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpressionPredictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialMolecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerBringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology.The Mysterious Ways of ErbB2/HER2 TraffickingNovel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
P2860
Q26861754-3638E018-9C65-4829-81DC-D2C6DD5AA93FQ27851725-8FF761AA-2BA5-4EF1-BF07-CEDA0FADC46EQ34613543-CDA3BDFE-695A-46FE-B2B7-E1552CC6C446Q35606679-331E2E11-31DB-4446-818A-589E49BF43CFQ36299086-BA6E0A94-BE7A-4797-9FD2-5C06514C243FQ36440214-267D0A92-6678-4FF1-8EC1-2F3F00956D1CQ38068491-166BBAC5-8B17-4A97-8855-946A18B39B45Q38237727-1B3DEF11-AAD8-4D9E-9165-BF4C235A61A0Q38736319-A57922F6-C0B2-4C32-8813-745BDF1B1286Q39207632-7C186073-5324-4160-AB8F-5551FA4FBDC5
P2860
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Lapatinib, a dual HER1/HER2 ty ...... ER2-driven cancer cell growth.
@en
Lapatinib, a dual HER1/HER2 ty ...... ER2-driven cancer cell growth.
@nl
type
label
Lapatinib, a dual HER1/HER2 ty ...... ER2-driven cancer cell growth.
@en
Lapatinib, a dual HER1/HER2 ty ...... ER2-driven cancer cell growth.
@nl
prefLabel
Lapatinib, a dual HER1/HER2 ty ...... ER2-driven cancer cell growth.
@en
Lapatinib, a dual HER1/HER2 ty ...... ER2-driven cancer cell growth.
@nl
P2093
P356
P1476
Lapatinib, a dual HER1/HER2 ty ...... ER2-driven cancer cell growth.
@en
P2093
Alejandro Vazquez-Martin
Cristina Oliveras-Ferraros
Javier A Menendez
Silvia Cufí
Sonia Del Barco
P2860
P356
10.1002/JCP.22333
P577
2011-01-01T00:00:00Z